White Shield

INTEREST-BASED ADS

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?

Patients HCP
This site is for US residents only.
Image of man holding a golf club in front of PLUVICTO "V" with a woman behind him and text reading,"About PLUVICTO" to his right

What is PLUVICTO and how does it work?

PLUVICTO is not chemotherapy.

It is the FIRST and ONLY radioligand therapy (RLT) for PSMA+ mCRPC.

  • RLT is a different type of radiation therapy that targets a biomarker called PSMA, which is present on many prostate cancer cells and also some healthy cells 

  • This means it is designed to find and attack PSMA+ cells, including cancer cells*

*May also damage PSMA+ and other nearby cells.

 

Think of it in 3 steps

ATTACH: PLUVICTO attaches to PSMA proteins on the outside of a cell.

PLUVICTO mechanism of action 1

ABSORB: Then PLUVICTO is absorbed into the cell.

PLUVICTO mechanism of action 2

ATTACK: From inside the cell, PLUVICTO attacks. It releases radiation into its target, the PSMA+ cell, damaging or destroying with limited damage to surrounding cells.

PLUVICTO mechanism of action 3
mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.